Tax Repatriation for Biotechs: Is it Deja Vu All Over Again?
By Peter Winter
Monday, August 12, 2013
Now that biotechnology has become a truly global enterprise, a significant number of U.S. biopharmaceutical companies are generating revenues in addition to their U.S. operations . . . and these overseas cash reserves are piling up.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.